US2007116647A1PendingUtilityA1

Medicinal preparation particularly for the treatment of slipped discs hernias

Assignee: THERON JACQUESPriority: May 7, 2002Filed: May 7, 2003Published: May 24, 2007
Est. expiryMay 7, 2022(expired)· nominal 20-yr term from priority
A61P 43/00A61P 35/00A61P 19/08A61K 9/0085A61K 49/0409
39
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention concerns a product consisting in an injection medicinal formulations comprising at least one compound to provide a viscous formulation, ethanol and at least one compound making said formulation opaque to X rays so as to control its delivery and its action. Said formulation is in particular useful for treating herniated invertebral discs but also in intervention having demonstrated the efficacy of pure ethanol: treatment of hepatocellular tumours or osteoid osteomas, renal cysts and arterial-veinous angiomas.

Claims

exact text as granted — not AI-modified
1 . Viscous injectable preparation, comprising at least one compound to give a viscous preparation, ethanol and at least one compound to make said preparation opaque to X-rays, said compound used to give a viscous preparation soluble in cold ethanol.  
   
   
       2 . Preparation according to  claim 1 , wherein said compound used to give a viscous preparation is ethylcellulose.  
   
   
       3 . Preparation according to  claim 2 , wherein ethylcellulose is used at a concentration ranging from 0.5 to 15%, preferably 5.88%, by weight of the preparation's total weight.  
   
   
       4 . Preparation according to  claim 1 , wherein said compound making said preparation opaque to X-rays is an inert compound.  
   
   
       5 . Preparation according to  claim 4 , wherein said compound making said preparation opaque to X-rays is tantalum oxide.  
   
   
       6 . Preparation according to  claim 4 , wherein said compound making said preparation opaque to X-rays is tungsten oxide.  
   
   
       7 . Preparation according to  claim 1 , wherein said ethanol has a purity of 70 to 99% by volume, preferably 95%.

Join the waitlist — get patent alerts

Track US2007116647A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.